Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide

Ivana N. Micallef(Mayo Clinic), Peter A. McSweeney(Mesoblast (United States)), Sachin Marulkar(Community Catalyst), Anthony D. Ho(Heidelberg University), Leonard M. Klein(Advocate Lutheran General Hospital), P J Gandhi

Bone Marrow Transplantation

May 17, 2010

10.1038/bmt.2010.118

Cited by 61

Related Papers

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

|New England Journal of Medicine|2017|6k

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

|The Lancet Oncology|2018|2.3k

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

|New England Journal of Medicine|2020|1.9k

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

|Blood|2001|1.4k

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

|The Lancet Oncology|2008|1.1k